608results about How to "Reduce apoptosis" patented technology

Compositions and methods are provided for modulating the expression of bcl-x. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bcl-x are preferred. Methods of using these compounds for modulation of bcl-x expression and for treatment of diseases associated with expression of bcl-x are also provided. Methods of sensitizing cells to apoptotic stimuli are also provided.

Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.

The present invention relates to novel quinoxaline, quinazoline and phthalazine derivatives as well as multimeric derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds for the treatment and prevention of brain damage resulting from brain injury, especially secondary brain damage due to traumatic brain injury (TBI). The compounds of the invention are also useful in treating and preventing neurodegenerative diseases.

The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and / or antagonists of DR4 activity.

The present invention provides methods and direct cardiac contact diastolic recoil device to improve diastolic recoil of a heart and includes a biocompatible film attached to or enclosing one or more structural elements that store elastic energy during heart contraction and release energy during heart filling.

The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt / β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

The invention discloses thermosensitive hydrogel loaded with copper metal organic skeleton nanoparticles and a preparation method of the thermosensitive hydrogel. The preparation method comprises thesteps that an amino group on gelatin and methacrylic anhydride are subjected to acylation reaction to synthesize methylacrylic esterified gelatin with a branch containing a carbon-carbon double bond,the carbon-carbon double bond on the branch and N-isopropyl acrylamide are subjected to free radical polymerization, and methylacrylic esterified gelatin-g-poly N-isopropyl acrylamide is prepared; 1,3,5-benzene tricarbonic acid and copper acetate monohydrate are used for preparing copper-based MOF nanoparticles; the copper-based MOF nanoparticles are added to a methylacrylic esterified gelatin-g-poly N-isopropyl acrylamide solution, and a product is prepared. Copper ions are embedded in the biodegradable thermosensitive hydrogel in the form of HKUST-1 NPs, controlled slow release of the copperions is achieved, cytotoxicity is effectively reduced, migration of in-vitro dermal cells is promoted, angiogenesis is induced, and wound healing is promoted.

The invention relates to the discovery that the proliferation and survival of pancreatic progenitor cells can be enhanced by contacting the cells with, (1) a caspase inhibitor sufficient to reduce apoptosis in the pancreatic endocrine cells; and, (2) a growth factor in an amount sufficient to increase the level of activated Akt in the pancreatic endocrine cells.

The present invention relates to novel quinoxaline, quinazoline and phthalazine derivatives as well as multimeric derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds for the treatment and prevention of brain damage resulting from brain injury, especially secondary brain damage due to traumatic brain injury (TBI). The compounds of the invention are also useful in treating and preventing neurodegenerative diseases.

Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.

A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1 / Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.

The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as "TNFR-5" or "TR5," and now referred to hereinafter as "TRAIL receptor without intracellular domain" or "TRID." TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.

As described below, the present invention features methods for reprogramming somatic cells and related therapeutic compositions and methods.

The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as "TNFR-5" or "TR5", and now referred to hereinafter as "TRAIL receptor without intracellular domain" or "TRID." TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.

The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21) compound and a Glucagon-Like Peptide 1 (GLP-1) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of beta cells ex vivo in the presence of free fatty acids, on caspase activity of beta cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db / db mice in vivo.

The invention relates to a separation and efficient amplification culture method for an antigen specific T lymphocyte. By means of the immunomagnetic bead technology and the character of an active T cell expression CD137, the antigen specific T lymphocyte is separated from a complex cell mass; then an antigen specific T lymphocyte with high tumor killing activity is obtained through in-vitro efficient amplification culture. CD137L (CD137-ligand), IL-7, IL-15 and IL-2 are added in the culturing process, so that the phenomenon that activated and induced cells are liable to apoptosis in the culturing process is avoided, the amplification time is increased, and the killing activity of the antigen specific T lymphocyte is improved.

A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a fusion protein selected from the group consisting of GLP-1 / IgG or variant or fragment thereof and an Ex4 / IgG or variant or fragment thereof and an autoimmune suppressor for silencing an autoimmune response against islet beta cells.

The invention provides an umbilical cord tissue cryopreservation and resuscitation method. The method comprises the following steps: S1, cutting umbilical cord tissues to obtain first tissue strips; S2, immersing the first tissue strips in a vitrification solution, and then directly cryopreserving the first tissue strips to obtain second tissue strips; and S3, resuscitating the second tissue strips to obtain third tissue strips, wherein the vitrification solution includes a first vitrification solution, a second vitrification solution and a third vitrification solution, and the step S2 includes the following processes: sequentially immersing the first tissue strips in the first vitrification solution, the second vitrification solution and the third vitrification solution, transferring thefirst tissue strips into liquid nitrogen, and cryopreserving the first tissue strips to obtain the second tissue strips. The umbilical cord strips are cryopreserved and resuscitated through a vitrification technology, so the operation time is shortened, the cryopreservation efficiency is improved, and the necrosis rate of the umbilical cord tissues in the cryopreservation and resuscitation processis reduced.

The invention relates to a drinking type acidulant and a preparation method and application thereof. Each 100ml of the acidulant contains components of 15-25ml of formic acid, 25-35ml of lactic acid,15-25g of citric acid, 5-15g of fumaric acid, 1-8g of calcium formate, 1-8g of sodium butyrate and the balance deionized water, wherein all of the components are 100ml. The preparation method comprises the following steps of performing injection according to the amount of 50-80% of the total amount of water to a stirring tank, starting a power supply, performing stirring at 120r / min, slowly addingthe fumaric acid, then adding the calcium formate and the sodium butyrate, performing stirring for 15min, after the fumaric acid, the calcium formate and the sodium butyrate sufficiently dissolve inthe water, slowly adding the citric acid, the lactic acid and the formic acid separately, and finally, adding the remaining water for uniform stirring so as to obtain products. Compared with the priorart, the drinking type acidulant contains various organic acid and organic acid salts, can regulate the acid of a ration system, can reduce the pH value of the digestive tracts of animals, can improve the activity of digestive enzymes, can promote the digestion of nutrient substances, can effectively control diarrhoea of piggies at the weaning and child care period, can regulate the intestinal microecology balanced, and can promote growth of the piggies at the weaning and child care period. Besides, when the drinking type acidulant is drunk, growth and propagation of pathogenic microorganismsin animal organisms, feeds and environment can be greatly reduced, and the usage amount of antibiotics can be directly reduced, so that drug tolerance, remaining and pollution problems caused by antibiotics can be reduced.

The invention relates to the field of human xenotransplantation model research, in particular to a method for establishing a human tumor xenotransplantation model cultured in vitro. The establishing method includes the following steps: (1) collecting a tumor tissue sample; (2) placing a tumor tissue in a culture solution; (3) completing the preparation for low-temperature transportation and treatment; (4) cutting the tumor tissue into grain size in a sterile operating table; (5) cleaning the tumor tissue and then placing the tumor tissue in a hole plate 48 for culture; (6) detecting tissue apoptosis by in situ end labeling method; (7) selecting immunocompromised NCG mice to perform anesthesia and skin treatment; (8) implanting the cultured tumor tissue into the renal capsule of the mice; (9) completing modeling after 3 months. According to the invention, tumor tissue blocks are selected for modeling for the xenotransplantation model, which is beneficial to preserving the histopathological and genetic characteristics of primary tumors; and moreover, the obtained tumor tissue are cultured in vitro, which is beneficial to tumor typing and clinical practice; the addition of PD 98059 and artificial matrix glue can greatly reduce tissue apoptosis, which is beneficial to improving the success rate of transplantation.

A Chinese medicine for treating senile weakness, deficiency of kidney's vital function, impotence, emission, ejaculation praecox, dizziness, etc is prepared from 13 Chinese-medicinal materials including red ginseng, male silkworm moth, wolfberry fruit, mulberry fruit, etc.

The invention relates to a cosmetic and / or pharmaceutical composition comprising, in a physiologically suitable medium, a carob peptide extract (Ceratonia siliqua L.) as an active agent for promoting aquaporin expression. The present invention also relates to the use of a carob peptide extract (Ceratonia siliqua L.), as an active agent for promoting aquaporin expression, in a cosmetic composition for improving the moisturization and the barrier function of the epidermis and for stimulating skin regeneration. The invention also relates to the use of this novel active agent for preparing a pharmaceutical, in particular dermatological, composition for regulating and / or stimulating aquaporin activity. The invention also relates to a cosmetic treatment method for preventing or combating dryness of the skin and mucous membranes and the manifestations of skin aging.

A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1 / Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.